236 articles 4 sections last published 2026-08-31 independent · no sponsored placements

Fund index

CTA

3 articles on this site analyse CTA — 1 of them head-on.

Measured concentration

as of 2026-06-30
54 Holdings (nominal)
1.6 Effective holdings
34× Overstatement
99.48% Top 10 weight

CTA reports 54 positions, but the weights make it behave like about 1.6 equally weighted ones. Computed by this site from the fund's SEC Form N-PORT filing — see what this measure does not tell you and the full table.

The same filing says what kind of price those positions carry: 100% of CTA is held at a quoted market price, across 4 issuer countries . Comparisons across every fund are in the valuation table, and what a low share does and does not mean is worth reading before drawing a conclusion from it.

Every filing since 2022

18

Between 2023-12-29 and 2026-06-30, CTA went from behaving like 1.8 equally weighted positions to 1.6 — 11% fewer, while its top ten went from 96.16% to 99.48% of net assets. Read across the funds on the concentration-over-time table.

PeriodHoldingsEffective Top 10Largest
2026-06-30 54 1.6 99.48% 79.03%
2026-03-31 79 1.2 155.28% 67.47%
2025-12-31 75 1.2 103.83% 90.76%
2025-09-30 53 2.7 97.09% 49.2%
2025-06-30 30 4.4 100.32% 34.48%
2025-03-31 54 2.8 130.03% 34.89%
2024-12-31 50 3.4 97.9% 43.73%
2024-09-30 50 2.1 99.98% 57.09%
2024-06-28 31 1.4 95.27% 84.72%
2024-03-28 * 30 1.4 93.28% 83.02%
2023-12-29 22 1.8 96.16% 70.76%
2023-09-29 * 43 2.5 92.16% 60.5%
2023-06-30 * 33 3.8 88.95% 38.19%
2023-03-31 * 28 4 85.77% 37.06%
2022-12-30 * 28 4.6 86.54% 33.3%
2022-09-30 * 29 5.5 88.94% 29.59%
2022-06-30 * 35 4.1 76.27% 45.26%
2022-03-31 * 12 36897.8 1.39% 0.27%

One row per filed reporting period, newest first, read from EDGAR. Quarterly because that is the public filing cadence. Rows marked * are published but held out of the comparison above; the methodology page says when and why.

Most often compared against

1

All articles

3

Mentions are detected across the full text of every article, so an appearance may be a passing comparison rather than the subject. Nothing here is a recommendation to buy or sell — see the disclaimer.